APOE4 Gene Linked to Early Neuronal Changes and Alzheimer's Risk
Millions of individuals carry the APOE4 gene, recognized as the strongest genetic risk factor for Alzheimer's disease. Recent research conducted by scientists at the Gladstone Institutes has uncovered that this gene variant may begin to influence brain activity well before any noticeable memory problems manifest. Their findings, published in the journal Nature Aging, outline a molecular sequence that could elucidate these early effects and hint at possible methods for reversing some of the changes.
In a study involving mouse models, the researchers discovered that the presence of APOE4 leads to an increase in the production of a protein known as Nell2. Elevated levels of Nell2 resulted in neurons becoming smaller and exhibiting unusual levels of activity. Notably, mice that displayed the highest levels of brain hyperactivity during their youth later experienced the most severe memory impairments.
The research team took steps to reduce the production of Nell2 and observed that even in adult mice carrying the APOE4 gene, neurons began to return to a more typical size and firing behavior. This finding raises the possibility that future therapies targeting Nell2 could assist individuals with APOE4 who are at an increased risk of developing Alzheimer's disease.
Misha Zilberter, PhD, a principal staff research scientist at Gladstone and a senior author of the study, stated, "To the best of our knowledge, this is the first study that has directly examined what APOE4 does to the function of neurons at different ages. We found fundamental changes in brain circuits occurring in young mice that still had normal learning and memory, and importantly, that those changes predicted the development of cognitive deficits at older ages."
APOE4 is one of three common forms of the APOE gene, yet it has a significantly stronger association with Alzheimer's risk compared to the others. Approximately one in four people carry the APOE4 variant, which is estimated to be present in 60 to 75 percent of individuals diagnosed with Alzheimer's disease.
Yadong Huang, MD, PhD, associate director of the Gladstone Institute of Neurological Disease and another senior author of the study, remarked, "This study is a big breakthrough for the field of Alzheimer's research. It opens the door to a better understanding of how APOE4 alters the function of neurons at a young age to increase risk of cognitive decline, and to the development of therapies that could block the detrimental effects of APOE4 early on."
Prior research had already indicated signs of unusually high brain activity in individuals carrying the APOE4 gene before reaching middle age, with this early hyperactivity linked to subsequent cognitive decline. However, the mechanisms by which APOE4 induces these cellular changes and their contribution to memory issues later in life remained unclear.
To address this, the researchers analyzed brain activity recordings in young mice and examined individual neurons. They found that young mice with the APOE4 variant exhibited excessive neuronal activity in two critical areas of the hippocampus, a region essential for memory. Interestingly, these same hippocampal areas have also shown hyperactivity in humans carrying the APOE4 gene.
The extent of hyperactivity in these young mice was predictive of their performance on spatial learning and memory tests later in life. The researchers also compared these subjects to mice carrying the APOE3 variant, which is associated with a lower risk of Alzheimer's disease. They observed that neurons in the affected brain regions were smaller in APOE4 mice than in those with APOE3. Smaller neurons tend to be more responsive to stimulation, increasing the likelihood of excessive firing.
While the neurons in APOE3 mice eventually became more excitable as they aged, this change did not occur until much later in life. This suggests that APOE4 accelerates a process resembling normal aging, potentially explaining why individuals with this gene variant are more prone to developing Alzheimer's disease earlier.
The research indicated that the hyperactivity associated with APOE4 was driven by the gene's expression within neurons rather than astrocytes, which are supportive cells in the brain. Zilberter noted, "When we deleted the APOE4 gene from astrocytes, nothing changed. But when we deleted it from neurons, the cells became larger and started functioning normally again."
The team then sought to identify the molecular process that caused the neurons with APOE4 to become smaller and more excitable. Their analysis highlighted Nell2 as a key factor, as it was found at elevated levels in neurons carrying the APOE4 variant. By employing CRISPRi, a technique that reduces gene activity without altering DNA permanently, they were able to lower Nell2 levels in hippocampal neurons from adult APOE4 mice. Following this reduction, the neurons increased in size and exhibited less excitability, indicating that elevated Nell2 is responsible for the excessive neuronal activity observed in brains with APOE4.
Nell2 had not been previously studied in direct connection with APOE4; however, earlier research had shown that higher levels of this protein were present in the brains of Alzheimer's patients, with greater amounts correlating with poorer cognitive function. Huang expressed enthusiasm about the implications of their findings, stating, "What's exciting about Nell2 is that we were able to reverse the disease manifestations in adult mice by lowering its level. That tells us the damage is not irreversible, and that there may be a window for intervention even after disease processes have been triggered."
This research was supported by various grants from the National Institute on Aging, the National Institute of Neurological Disorders and Stroke, and the National Center for Research Resources.




